Khiron closes $28.8 million bought deal financing including full exercise of over-allotment option

28 February 2019

On Feb. 28, 2019, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) announced that it had closed its previously announced bought deal short form prospectus offering of common shares, including the exercise in full of the over-allotment option for aggregate gross proceeds of $28,842,000. The offering was completed by a syndicate of underwriters co-led by Canaccord Genuity Corp. and BMO Nesbitt Burns Inc., and including Cormark Securities Inc.

Khiron is positioned to be a dominant integrated medical cannabis company in Latin America. The company has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018, Khiron listed on the TSXV, becoming the first Colombian based medical cannabis company to trade on any exchange globally.

Gowling WLG advised Khiron with respect to this financing with a team led by Peter Simeon and that included Marek Lorenc and Sachin Seth.


NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.